fashion -WSS

fashion

author：explore 2025-09-04 05:34:38 - browse：4947

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Schizophrenia gene found to be linked to cells' energy dysfunction

focus

WSS

3 hurdles to bringing medical devices to the U.S. market

Weight bias in eating disorder treatment complicated by new weight loss drugs

Cloning humans is technically possible. It's curious no one has tried

STAT's guide to the next generation of CAR

Aspartame and sugar

The battle over the Brookhaven Landfill on Long Island

knowledge

fashion

knowledge

Dobbs anniversary: the lost opportunity of abortion as health care

Treatments for cramps don't cut it. Why aren't there better options?

United colonoscopy coverage change 'may cost lives,' doctors say

YouTube cracks down on misinformation on cancer treatment

Hollywood unions extend contract negotiations for actors

The story of mRNA: From a loose idea to a tool that may help curb Covid

The cancer drug shortage isn’t new — and neither are the solutions

Surge in Apellis stock fueled by confidence in safety of its eye drug

Trump demands the U.S. pay no more for drugs than other countries … again

What to know about the judge who will handle the Trump case

knowledge

The strategy behind pharma's lawsuits over drug pricing reform

WATCH: Why do fingernails fall off when they're damaged?

Colonoscopy at 40? Study finds a possible benefit

Megan Rapinoe shares emotional post following US Women's World Cup exit

Maui wildfire now ranks as the fifth

3 hurdles to bringing medical devices to the U.S. market

focus

focus

Wikipedia

focus